Hefiya®

ACTIVE PRINCIPLE:
Adalimumab

INDICATION:
Ankylosing spondylitis
Arthritis
Uveitis
Rheumatoid Arthritis
Hidradenitis suppurativa
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
Psoriasis

DATE:
26/07/2018

STATUS:
Authorized

MORE INFORMATION